Dabur Research Foundation (DRF) is an Indian Contract Research Organization offering preclinical services in Drug Discovery and Development, ranging from identification of potential lead molecules, drug development to IND enabling studies. We offer preclinical services to global Biotech, Pharma, Phytopharmaceuticals Cosmeceuticals, and academia sectors Read More
The core team of DRF looks back on more than 20 years of their experience in conducting preclinical studies and commercializing molecules.
Read MoreDabur Research Foundation offers various in vitro or ex vivo models serving as alternatives to animal testing by focusing on the 3R’s principle
Read MoreDabur Research Foundation recognizes the need for out of the box thinking to enable for rapid & cost effective preclinical development of molecules
Read MoreDRF has designated laboratories for Necropsy, biochemistry and histopathology equipped with state of art/fully automatic equipments such as hematology analyzer, biochemistry analyzer, coagulation analyzer, tissue processor, microtome and etc. know More
In a campuse of approximately 60000 square feet area Dabur Research Foundation is a one-stop shop for your preclinical needs. The state-of-the-art GLP facility is ready having 19 experimental rooms. This facility is centrally know More
The state-of-art instrumentation lab at DRF provides in depth analytical services to support the analytical needs for API, NCEs, Agrochemical Testing (physicochemical Testing and five Batch Analysis), UVCB’s, CMC testing, Herbal drug characterization, DMPK (Drug Metabolism and Pharmacokinetics, Bioanalysis), other chemical analysis. Know More
Date: 28th March 2024
Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development.
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF Lifesciences, an established contract research organisation, aimed at combining the strengths of Partex's advanced AI & data services technology and Althea’s screening services and compounds.
The immediate scope of this exciting partnership is to provide end-to-end services from AI-driven drug discovery to wet lab validations to accelerate drug development.
Dr. Gunjan Bhardwaj, CEO of Partex, expresses enthusiasm about this innovative collaboration, stating, “We have been following Althea for quite some time and this collaboration is a logical next step for both companies in driving innovation in drug discovery. It will allow us to further strengthen our product development in many ways, and it will drive more future innovations.”